GLENMARK NEWS
Stock market update: Nifty Pharma index advances 0.09% in an upbeat market
The Nifty Pharma index was trading 0.09 per cent up at 20862.7.
Stock market update: Nifty Pharma index falls 0.17% in an upbeat market
The Nifty Pharma index was trading 0.17 per cent down at 20566.55.
Stock market update: Nifty Pharma index falls 0.6%
The Nifty Pharma index closed 0.6 per cent down at 20601.7.
Stock market update: Nifty Pharma index falls 0.78% in a weak market
The Nifty Pharma index was trading 0.78 per cent down at 20563.5.
Stocks in news: Nykaa, TCS, Tata Elxsi, Glenmark Life, YES Bank, Siemens
Markets fell half a percent. TCS, Tata Elxsi, Anand Rathi Wealth, and Akme Fintrade Q1 results are in focus. Canada Pension Plan sold Nykaa shares at Rs 174 apiece. Glenmark promoters to sell a 7.85% stake. Moody's affirmed YES Bank's Ba3 rating. Siemens and RVNL won the Bangalore Metro Rail Corp project. Kesoram posted a Rs 62 crore Q1 loss.
Stock market update: Nifty Pharma index advances 0.39%
The Nifty Pharma index closed 0.39 per cent up at 20725.95.
- Go To Page 1
Glenmark Pharma to sell 7.84% stake in Glenmark Life via OFS
The stake sale will be done through the stock exchanges via an offer for sale (OFS). The decision was made at a meeting held today, and the company informed about the development after market hours.
Can Zaynich do for Wockhardt what Ozempic did for Novo Nordisk?
Wockhardt's Zaynich antibiotic surged stock by 75%. CEO Habil Khorakiwala cited its uniqueness; phase three trials end this fiscal year. Compared to Novo Nordisk's Ozempic, Zaynich’s $25 billion potential counters global antibiotic resistance.
Technical Breakout Stocks: How to trade HDFC Bank, Glenmark Life and Federal Bank on Thursday?
Indian market hit fresh record highs on Wednesday tracking positive global cues. The S&P BSE Sensex hit a fresh record high above 80,000 for the first time while the Nifty50 climbed above 24300 levels. The Nifty50 rose 162 points to close at 24286 while the S&P BSE Sensex closed with gains of 545 points at 79,986.
India to make drugs for diabetes, obesity under PLI by 2026, says report
India plans to incentivize local manufacturing of GLP-1 drugs, crucial for treating diabetes and obesity, starting in 2026, as per a government official speaking to Reuters. These drugs, originally approved for diabetes treatment, are also used for obesity due to their ability to slow digestion and reduce appetite. Novo Nordisk's patent on semaglutide, a key ingredient in popular drugs like Wegovy and Ozempic, is set to expire in India by 2026. Indian companies are already preparing to manufacture these drugs under the government's production-linked incentive (PLI) scheme.
Ozempic frenzy lures rich Indians to brave the gray market
People are going to great lengths to obtain popular weight-loss drugs. They are stashing injectables in their carry-on luggage, buying counterfeit formulas online, and importing boxes from Europe. The treatments have sparked extensive media coverage, fueling a high demand. According to Goldman Sachs Research, the anti-obesity medication market could hit $100 billion by 2030. In contrast, Indians have largely been observers in this global frenzy over the new weight-loss solutions.
Ahead of June 4, be relatively light & in cash; curtail trading: Dipan Mehta
Dipan Mehta advises caution and light trading ahead of the upcoming election dates. He emphasizes the importance of being in cash and watching the election results closely for investment decisions.
IndiGo, Adani Ports among 5 stocks with short buildup
A short buildup is when there is a rise in open interest and volumes along with a decrease in the price of the underlying stock in the Futures and Options segment. Short buildup means more people are expecting the prices to go down and creating short positions. In Friday's trading session, five stocks witnessed a build of fresh short positions. Here's the list:
F&O stocks: Godrej Consumer Products, Cipla among 5 stocks with short buildup
In Tuesday's trading session, the following five stocks witnessed a build of fresh short positions. Let us first understand how this conclusion is reached that whether the stock has seen a buildup of fresh short position or not.
National Aluminium, Dalmia Bharat among 5 stocks with short buildup
A short buildup is when there is a rise in open interest and volumes along with a decrease in the price of the underlying stock in the Futures and Options segment. Short buildup means more people are expecting the prices to go down and creating short positions. In Tuesday’s trading session, five stocks witnessed a build of fresh short positions. Here's the list:
Ashok Leyland, Apollo Hospitals among 5 stocks with short buildup
A short buildup is when there is a rise in open interest and volumes along with a decrease in the price of the underlying stock in the Futures and Options segment. Short buildup means more people are expecting the prices to go down and creating short positions. In Thursday’s trading session, five stocks witnessed a build of fresh short positions. Here's the list:
Glenmark recalls 6,528 bottles of blood pressure drug in US
As per the USFDA, a Class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
NTPC, Glenmark Pharma among 5 stocks with long buildup
A long buildup occurs when there is an increase in open interest and trading volumes alongside a rise in the price of the underlying stock in the Futures and Options segment, indicating a bullish trend in the market. In Friday's trading session, five stocks experienced a buildup of fresh long positions. Here's the list:
This smallcap mutual fund added 12 new stocks in February while exiting 7 others
Bandhan Small Cap Fund-Reg(G) revamped its portfolio in February with new stock additions and exits. The scheme, benchmarked against S&P BSE 250 Smallcap TRI, had significant exposure in Juniper Hotels, Eureka Forbes, and The South Indian Bank, managing assets of Rs 4,389.28 crore.
Reduce Glenmark Pharmaceuticals, target price Rs 780: ICICI Securities
Glenmark Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Other Operating Revenue and Sale of services for the year ending 31-Mar-2023.
Hot Stocks: Brokerage view on Kotak Mahindra, Glenmark Pharma, Biocon and RIL
The risk-to-reward ratio is unfavourable at current levels. Earnings downgrades will continue due to a lack of new launches.
Stocks in news: Embassy REIT, Nippon AMC, BPCL, Apollo Tyres
Global private equity firm Blackstone Group plans to sell its entire stake in Embassy Office Parks REIT through a mega block deal on Wednesday, according to news reports
CCI approves Nirma's acquisition of Glenmark Life Sciences
The acquisition will trigger a mandatory open offer to all public shareholders of GLS for an additional 17%.
Stocks to buy today: 9 short-term trading ideas by experts for 18 December, 2023
For today, analyst Rupak De, LKP Securities said that the prevailing sentiment appears strongly in favor of the bulls, as indicated by the absence of any reversal signals on the technical charts. Resistance is observed at 21,500, while a potential further rally in the Nifty could occur upon breaching this level, he said, adding that the support is currently positioned at 21,300.
F&O stocks: Polycab, DLF among 5 stocks with long buildup
Glenmark Pharma topped the list, the stock price gained 3.4% and open interest saw an increase of 2.96%. Polycab stock price gained 2.86% and open interest saw an increase of 0.81%.
Reduce Glenmark Pharmaceuticals, target price Rs 660: ICICI Securities
Glenmark Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Other Operating Revenue and Sale of services for the year ending 31-Mar-2022.
Stocks in news: Vedanta, Glenmark Life, ICICI Lombard, SAMHI Hotels, Zaggle Prepaid
India's JSW Steel Ltd , is slowing down the process to buy a stake in the steelmaking coal unit of Canada's Teck Resources, Reuters reported, in the first sign that a diplomatic spat is affecting trade ties.
Glenmark Pharma to sell 75% stake in Glenmark Life to Nirma for Rs 5,652 crore
Glenmark Pharmaceuticals will sell 9,18,95,379 shares in the subsidiary at Rs 615 a share. The 75% stake sale in Glenmark Life Sciences will trigger an open offer to the minority shareholders of the company, as per the regulatory norms
Glenmark settles drug pricing case with US Department of Justice
US-based Glenmark Pharmaceuticals Inc, a subsidiary of the company, has entered into a three-year deferred prosecution agreement with DOJ involving historical pricing practices by former employees relating to the generic drug pravastatin between 2013 and 2015
Load More
